KIR3DL1

ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023

Retrieved on: 
Monday, December 11, 2023
ESMO, Neoplasm, Immune system, LILRB2, CD47, HLA, Alpha globulin, Doctor of Philosophy, Therapy, KIR3DL1, CDO, Cancer, Inflammation, Myelocyte, CSO, Patient, LILRB1

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – December 11, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.

Key Points: 
  • Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – December 11, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.
  • “We already have encouraging in vitro data demonstrating potent anti-tumor efficacy and primary cell data demonstrating an enhanced safety profile compared to competing CD47 targeting molecules,” said Osiris Marroquin Belaunzaran, PhD, CSO and co-founder of ImmunOs Therapeutics.
  • “We believe that HLA molecules can serve as a versatile backbone to develop novel therapies capable of stimulating the immune system of cancer patients to eliminate tumor cells.
  • Moreover, we are also utilizing specific HLA molecules to develop novel therapies to treat inflammatory diseases.”

ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002

Retrieved on: 
Tuesday, October 24, 2023
ESMO, Therapy, Infrared spectroscopy correlation table, Trial of the century, KIR3DL1, Pembrolizumab, PD-1, Inflammation, Pharmacokinetics, LILRB1, LILRB2, ILT2, DLT, Safety, Cancer, CMO, ILT4, Patient, Immuno-psychiatry, Pharmaceutical industry, MD

The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.

Key Points: 
  • The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.
  • A second cohort of IOS-1002 in combination with pembrolizumab will be initiated after completion of the fifth dose level.
  • The Phase 1a/b trial is expected to enroll over 120 patients.
  • "We are pleased that the trial is progressing as planned," said Christoph Renner, M.D., CMO and co-founder of ImmunOs Therapeutics.

ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA

Retrieved on: 
Tuesday, October 17, 2023
LILRB1, Merck Sharp & Dohme Federal Credit Union, Immuno-psychiatry, Pembrolizumab, Inflammation, Therapy, Merck & Co., Safety, ILT4, Cancer, LILRB2, Merck, HLA, KIR3DL1, ILT2, Patient, Pharmaceutical industry, MD

IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.

Key Points: 
  • IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.
  • ImmunOs is currently enrolling patients in the Phase 1a/b trial, initiated earlier this year, to evaluate the potential of IOS-1002 as a monotherapy and in combination with KEYTRUDA in adult patients with advanced solid tumors.
  • “We are pleased to enter into this agreement for our ongoing Phase 1a/b trial of IOS-1002,” said Christoph Renner, M.D., Chief Medical Officer, and co-founder of ImmunOs.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002

Retrieved on: 
Wednesday, May 24, 2023
LILRB1, ILT2, University, Therapy, LILRB2, HLA, University of Melbourne, Cancer, Pharmacokinetics, Immuno-psychiatry, ILT4, Patient, Immune system, Peter MacCallum Cancer Centre, Trial of the century, KIR3DL1, Safety, Vaccine, Pharmaceutical industry

Schlieren (Zurich Area), Switzerland – May 24, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia.

Key Points: 
  • Schlieren (Zurich Area), Switzerland – May 24, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia.
  • IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 for the treatment of advanced solid tumors.
  • Primary endpoints of the current Phase 1a, first-in-human, open-label, non-randomized, multicenter study will be the safety and tolerability of IOS-1002.
  • "We are excited that our lead compound IOS-1002 has entered into a first-in-human trial and that patients are being dosed," said Sean R. Smith, CEO of ImmunOs Therapeutics.

ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002

Retrieved on: 
Tuesday, January 17, 2023
ILT2, Degenerative disease, Schlieren, ILT4, LILRB2, TGA, Therapeutic Goods Administration, Therapy, Immuno-psychiatry, KIR3DL1, Pharmacokinetics, Safety, Macrophage, NK, HLA, Patient, Cancer, PD-1, Pharmaceutical industry

In the trial, the compound will be administered at various dose levels to patients with advanced solid tumors either as monotherapy or in combination with a PD-1 monoclonal antibody.

Key Points: 
  • In the trial, the compound will be administered at various dose levels to patients with advanced solid tumors either as monotherapy or in combination with a PD-1 monoclonal antibody.
  • "Advancing our lead compound IOS-1002 into a first-in-human trial is a major milestone for our team and provides a potential new option for patients," said Sean R. Smith, CEO of ImmunOs Therapeutics.
  • "We are excited about the opportunity to evaluate IOS-1002 in patients, as the compound addresses key challenges in cancer immunotherapy.
  • We believe it has the potential to help patients with advanced solid tumors who have no further treatment options."

ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro

Retrieved on: 
Tuesday, November 15, 2022
Degenerative disease, Phagocytosis, LILRB2, Immune system, Macrophage, Lightspeed Venture Partners, Antibody, HLA, Therapy, Patient, PEGS, KIR, Protein, Autoimmunity, LILRB1, NK, ILT4, Cancer, KIR3DL1, ILT2, HCV, HIV, Immuno-psychiatry, Lymphatic system, Pharmaceutical industry, Vaccine, MD

November 15, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002.

Key Points: 
  • November 15, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002.
  • The presented data supports IOS-1002 as a first-in-class multi-functional agent which will enter a Phase 1 trial later this year.
  • "We are excited that our lead program IOS-1002 has generated such promising non-clinical data both as a monotherapy and in combination with anti-PD-1," added Sean R. Smith, Chief Executive Officer of ImmunOs Therapeutics.
  • ImmunOs lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses.

ImmunOs Therapeutics Raises $74 Million Series B Financing Round

Retrieved on: 
Tuesday, June 7, 2022
Degenerative disease, Saṃsāra, Iron Stone Strategic Capital Partners, Company, Series, LILRB1, ILT2, Doctor of Philosophy, Chairperson, Lightspeed Venture Partners, HLA, CEO, KIR, ILT4, Therapy, Patient, KIR3DL1, LILRB2, Immuno-psychiatry, Novartis, Immune system, Gimv, Antibody, Autoimmune disease, General partnership, Cancer, Vaccine, Pharmaceutical industry, MD, Speed of light

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA June 7, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million.

Key Points: 
  • Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA June 7, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million.
  • "We are delighted to close this significant financing round led by a group of top-tier U.S. and European investors," said Sean R. Smith, CEO of ImmunOs Therapeutics.
  • ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases.
  • ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases.

ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro

Retrieved on: 
Monday, November 15, 2021
SITC, Cancer, Macrophage, KIR, Therapy, University, Autoimmunity, Lymphatic system, HIV, KIR3DL1, Degenerative disease, Society, NK, LILRB1, ILT2, PD-1, Program, LILRB2, Phagocytosis, Association, Company, Immuno-psychiatry, HCV, Immunotherapy, HLA, Patient, ILT4, Pharmaceutical industry, Vaccine

November 15, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002 (formerly iosH2).

Key Points: 
  • November 15, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002 (formerly iosH2).
  • "We are excited that our lead program IOS-1002 has generated such promising preclinical data both as a monotherapy and in combination with PD-1," added Sean R. Smith, Chief Executive Officer of ImmunOs Therapeutics.
  • ImmunOs Therapeutics AG focuses on the development of a new class of biologic therapeutics for the treatment of cancer and autoimmune diseases.
  • ImmunOs Therapeutics lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses.